These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24777968)

  • 21. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.
    Redjimi N; Raffin C; Raimbaud I; Pignon P; Matsuzaki J; Odunsi K; Valmori D; Ayyoub M
    Cancer Res; 2012 Sep; 72(17):4351-60. PubMed ID: 22798340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
    Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
    Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
    Nishikawa H; Sato E; Briones G; Chen LM; Matsuo M; Nagata Y; Ritter G; Jäger E; Nomura H; Kondo S; Tawara I; Kato T; Shiku H; Old LJ; Galán JE; Gnjatic S
    J Clin Invest; 2006 Jul; 116(7):1946-54. PubMed ID: 16794737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
    Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
    Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
    Nishikawa H; Jäger E; Ritter G; Old LJ; Gnjatic S
    Blood; 2005 Aug; 106(3):1008-11. PubMed ID: 15840697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
    Fourcade J; Sun Z; Kudela P; Janjic B; Kirkwood JM; El-Hafnawy T; Zarour HM
    J Immunol; 2010 Jun; 184(12):6709-18. PubMed ID: 20483736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers.
    Ayyoub M; Pignon P; Dojcinovic D; Raimbaud I; Old LJ; Luescher I; Valmori D
    Clin Cancer Res; 2010 Sep; 16(18):4607-15. PubMed ID: 20670945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
    Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
    J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.